FSD Pharma’s Stock (NASDAQ: HUGE) Doubles, Biotech Company Fighting COVID-19

After FSD Pharma’s announcing an old drug test for COVID-19 treatment NASDAQ: HUGE tripled and now being traded at $8.78 with an increased volume of 12,009,662 shares.

FSD Pharma is a tiny biotech company like any other healthcare-related firm that strives in the race to create effective COVID-19 treatment technology; whether it is a device or vaccine. That old medicine that will go under testing is called ultramicronized PEA, made and sold in Europe in the 1970’s as a treatment for flu and cold. Except in Italy and Spain FSD owns rights to PEA worldwide. The drug belongs to another company that sells PEA as a medical food supplement in Spain and Italy.

Alex Krakowsky

